Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access Mylotarg for relapsed or refractory acute myeloid leukemia
2018-001321-68Phase 4
- Sponsor
- Pfizer
- Start
- May 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Acute promyelocytic leukaemia (APL), sponsored by Pfizer. Primary endpoints: Compassionate access objective and Safety monitoring.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on 2018-001321-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001321-68.